Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Diagnostic pact established

May 22, 2006 | A version of this story appeared in Volume 84, Issue 21

DeCode Genetics and Illumina have teamed up to develop and commercialize DNA-based diagnostics for several diseases. Illumina will use its high-multiplex single-nucleotide polymorphism (SNP) genotyping platform to develop tests for gene variants that deCode has already determined to be linked to risk of disease. The companies will first develop predictive tests for breast cancer, type 2 diabetes, and heart attacks. In addition, Illumina's SNP genotyping platform will be installed at deCode, enabling deCode to expand its contract genotyping business.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.